The multidrug transporter ABCG2: still more questions than answers

Aaron J. Horsey*, Megan H. Cox*, Sunehera Sarwat* and Ian D. Kerr*

*School of Life Sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, U.K.

Abstract
ABCG2 is one of at least three human ATP binding cassette (ABC) transporters which can facilitate the export from cells of a wide range of chemically unrelated drug molecules. This capacity for multidrug transport is not only a confounding factor in chemotherapy, but is also one of the more perplexing phenomena in transporter biochemistry. Since its discovery in the last decade of the 20th century much has been revealed about ABCG2’s localization, physiological function and its broad substrate range. There have also been many investigations of its structure and molecular mechanism. In this mini review article we take a Rumsfeldian approach to ABCG2 and essentially ask what we do know about this transporter, and what we will need to know about this transporter if we wish to use modulation of ABCG2 activity as a therapeutic approach.

Multidrug transporters in biology
Multidrug resistance (MDR) can be defined as the ability of cells or organisms to resist the cytotoxic effects of a diverse range of chemical structures, often with different intracellular targets. MDR is observed across the spectrum of infectious disease therapy, as well as being documented in cancer chemotherapy. In many cases, the acquisition of a MDR phenotype is a poor prognostic indicator. For example, the emergence of drug resistant pathogenic bacteria and the subsequent lack of effective therapies is one of the global challenges for the 21st century. MDR may manifest through many mechanisms, often operating with what one presumes to be a degree of synergy, including chemical modification of the drug molecule rendering it ineffective (or less effective) and the alteration of gene expression to enable cellular metabolism to proceed through other pathways. The mechanism of interest here is the export of the drug from the cell, thus preventing it from achieving clinically effective concentrations. MDR by drug export is catalysed by at least 5 (and almost certainly more) families of membrane proteins with examples well documented in antimicrobial, antiparasitic and anticancer chemotherapy [1].

In humans, MDR is most widely associated with the failure of cancer chemotherapy. A number of cancers have been shown to have poorer prognosis if there is either a pre-existing expression of an MDR pump, or if expression of an MDR pump develops as a result of chemotherapy (see section below). Several human ATP binding cassette (ABC) proteins have been well described to be capable of MDR, although doubtless there will be more from the 48 ABC proteins that comprise the family in humans. Three of these, ABCB1 (P-glycoprotein), ABCG1 (multidrug resistance protein 1) and ABCG2 (breast cancer resistance protein) have been the subject of many decades of investigation, and there are already numerous reviews on many facets of their structure, function, regulation and role in disease [2,3]. The aim here is not to provide an exhaustive overview of one of this triumvirate (ABCG2) but to present a personal view about what we know, and what we need to know about this transporter if we are to develop rational interventions in chemotherapy.

ABCG2 localization and physiological function: an incomplete picture
Although first isolated from multidrug resistant cancer cells, ABCG2’s expression and distribution pattern in normal tissues implies that it must fulfil important physiological roles, such as protecting the organism as a first line of defence against environmental toxins. Schinkel’s original study on ABCG2-null mice confirmed this role, demonstrating that these animals are more susceptible to diet-induced protoporphyra and phototoxicity, caused by accumulation of pheophorbide A [4], a chlorophyll degradation product and a confirmed ABCG2 transport substrate [5].

Extensive studies have continued to affirm that in humans and rodents, the localization of ABCG2 can play a vital role in limiting absorption (in the small intestine), mediating distribution (e.g. in the blood–brain and blood–placental barriers) and facilitating elimination and excretion (in the liver and kidney) of drugs or xenobiotics that are ABCG2 transport substrates. This specific ABCG2 distribution profile among the different types of tissues is closely related to the physiological role it assumes in the body. For instance, in the blood–brain barrier, ABCG2 is expressed highest on the luminal side of brain endothelial cells. Here, it serves...
as a crucial barrier to drug access, significantly limiting the penetration of drugs or xenobiotics into the brain [6,7], potentially in a synergistic manner with ABCB1 [8], with implications for brain tumour therapy and imaging [9].

In addition, ABCG2 is expressed in the apical membrane of epithelial cells in the gastrointestinal (GI) tract, with highest expression in the duodenum and a gradual decrease along the GI tract to the rectum. Here, ABCG2 plays an important role in limiting the absorption of orally administered anticancer drugs and ingested toxins [10,11]. In the liver canalicular membranes, where ABCG2 is constitutively expressed, a role in toxin and metabolite excretion is apparent [11,12]. In the human kidney ABCG2 is expressed on the apical membrane of proximal tubular cells, however with a lower expression level than that in the liver and the small intestine, and is responsible for urate export. Indeed, ABCG2 activity as a urate transporter is known to be abrogated in gout [13].

Among normal human tissues, ABCG2 is expressed highest on the apical membrane of the placental syncytiotrophoblasts. Here, ABCG2 expels drugs or xenobiotics from the foetal compartment back to the maternal circulation, limiting foetal exposure of the toxic substances and playing a major role in protecting foetus against maternally derived toxins [14]. ABCG2 is also expressed in the mammary gland being induced strongly during the lactation phase in mice, cows, and humans. It has been shown that ABCG2 actively transports not only beneficial vitamins (e.g. riboflavin) but also, seemingly paradoxically, toxic drugs and xenobiotics (e.g. topotecan, cimetidine and 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine) into breast-milk [15,16].

How do we develop a greater understanding of the tissue-specific roles of ABCG2? This question remains important to answer, particularly considering the impact of ABCG2 function on multiple drug pharmacokinetics and the potential for ABCG2 polymorphisms to have differential effects on transporter function (see below).

**ABCG2 transport substrate diversity and pharmacology: all mapped out?**

As discussed above, the exact physiological roles of ABCG2 remain somewhat enigmatic. The distribution of the transporter within tissues that have a predominantly secretory or barrier function leads to ABCG2 being recognised for a role in controlling the disposition and tissue exposure of endobiotics and xenobiotics, confirmed in numerous in vitro and in vivo studies. These include antibiotics, steroids, immune-suppressants (including anti-HIV drugs), fluorescent dyes (e.g. Hoechst 33342), photosensitizers (pheophorbide A and protoporphyrin IX). The increased expression of ABCG2 has been linked to MDR in cancer (see below) and there have also been numerous studies describing ABCG2 mediated transport of chemotherapeutic drugs including mitoxantrone, methotrexate, topotecan, flavopiridol and tyrosine kinase inhibitors (imatinib, gefitinib and nilotinib) [17].

At present, over 200 transport substrates of ABCG2 have been identified, with some attempts made to analyse structure–activity relationships (SAR). One such study demonstrated the impact of polarity on transport in a series of novel camptothecin analogues, which were actively extruded at a greater rate dependent on their higher polarity [18]. Additionally, small chemical libraries of ABCG2 inhibitors have been investigated to determine important functional groups. For example, inhibitors of casein kinase II were repurposed into a series of ABCG2 inhibitors by an overall increase in hydrophilicity and aromaticity [19]. This argument for polarity being associated with transport, and hydrophilicity with inhibition is interesting when taken alongside the most thorough attempt to determine the typical features of ABCG2 interacting compounds, presented in 2015 by Anna Seelig's group [20,21]. In two papers they employed functional ATPase activity assays, physicochemical data and molecular modelling to attempt to distinguish between the chemistries of ABCB1 and ABCG2 transport substrates. The authors argued that ABCG2 transports chemistries with higher hydrophilicity than ABCB1. However, in common with ABCB1, it does so subsequent to the partitioning of compounds from the aqueous to the lipid phase. A loose set of rules incorporating hydrophilicity, amphipathicity and ionization state was derived from analysis of a test series of chemicals to predict ABCG2's likely interaction with or inhibition by other compounds [21]. Given the hundreds of compounds within the repertoire of ABCG2's chemical interactome it would be interesting to see how these rules evolve with the acquisition of further data.

What do we know about how and where these drugs bind? The short answer: surprisingly little! Initial studies aimed to understand ABCG2 pharmacology, and included equilibrium and kinetic radioligand binding assays to study the interaction of radiolabelled daunomycin with ABCG2 expressed in insect (SF9) cell membranes [22]. This study was performed with an R482G mutant version of ABCG2 due to its broader substrate range (see below). The data demonstrated an affinity ($K_d$) of ABCG2 for daunomycin of approximately 100 nM, which is still the only quantitative demonstration of an affinity of ABCG2 for a transport substrate. Relative potencies for other drugs (mitoxantrone, Hoechst 33342, doxorubicin and prazosin) to displace daunomycin binding were obtained and led to a picture of multiple drug binding sites showing a complex network of allosteric communications [22]. Changes in transport substrate affinity were demonstrated in subsequent studies upon the binding, rather than the hydrolysis of ATP [23], but other direct, quantitative data for ABCG2:transport substrate interaction remain scarce.

In the absence of such data a great deal of time and effort has been put into in vitro site-directed mutagenesis studies of ABCG2. Arginine 482 to glycine/threonine (TM3; Figure 1) is a classic example of a mutation which impacts substrate binding and/or transport resulting in the ability
Figure 1 | Topology and functionally important residues of ABCG2

A monomer of ABCG2 consists of a 655 amino acid protein with a 250 amino acid intracellular N-terminal NBD, an uncharacterized linker region followed by six TMDs and associated intra and extracellular loops. Orange colours indicate where the experimental and predicted topology differ. A number of residues have been identified as significant including glycosylation site (green), stability affecting sites (red) and putative drug binding sites (yellow) in addition to the gout associated Q141K polymorphism are shown.

ABCG2 has over 80 single nucleotide polymorphisms (SNPs) residing within its gene coding region. The effect of ABCG2 polymorphisms on clinical pharmacology is a crucial area of current research; given the polyspecificity of the transporter it is inevitable that some polymorphisms will impact on the pharmacokinetics of particular drugs. Perhaps the most well documented of these is the rs2231142 polymorphism, Q141K. This polymorphism (which is associated with increase prevalence of gout [13]) has also been found to increase the bioavailability of topotecan, more than doubling the exposure to rosuvastatin, commonly used in the treatment of hypercholesterolaemia [28,29].

That a single polymorphism can lead to raised levels of drugs or metabolites by either inhibiting excretion (e.g. renal elimination of urate [13]) or inhibiting absorption (intestinal uptake of rosuvastatin [29]) is intriguing and presents a challenge in understanding drug pharmacokinetics. Clearly, the impact of other SNPs on ABCG2 expression, drug transport and selectivity will be an increasingly important area of research.

ABCG2 structure and oligomerization: building up the picture is taking time

Protein structure is vital for a full understanding of function and could provide an excellent basis for the design of drugs. For the ABC multidrug pumps which are targets for pharmacological intervention this will require high resolution crystal structures in several conformations, including with bound transport substrate. In the absence of this for ABCG2, we have had to rely on the evidence for the transporter’s membrane topology, its oligomeric state and available low resolution structural data, as the framework upon which to pin our understanding of mechanism.

Eukaryotic ABC transporters consist of at least one cytoplasmic nucleotide binding domain (NBD) and one transmembrane domain (TMD; Figure 1). The fundamental functional unit of ABC transporters requires the interaction of 2 NBDs to provide composite ATP binding sites, with contributions from both NBDs [30]. Eukaryotic ABC transporters meet this requirement either as ‘full transporters’, typically consisting of two homologous halves comprising a TMD-NBD-TMD-NBD arrangement, or...
as ‘half-transporters’ (comprising a single TMD-NBD) that form homo-dimers, hetero-dimers or higher order oligomers. The ABCG subfamily falls into the half-transporter category and have their TMD-NBD arrangement reversed. Subsequently, human ABCG2 is a reverse half transporter [31]. Six transmembrane helices are identified by consensus topology prediction algorithms and confirmed by epitope tagging, although there are differences in the predicted, compared with experimental, topology in terms of the location of TM2 and TM5 [32], which may be both shifted C-terminally with respect to the computer-based predictions (Figure 1). Whether this reflects the insertion of tags having an effect on the structure is unclear in the absence of further supporting evidence [2]. Without a high resolution structure, homology modelling has been used to assist in the interpretation of experimental data, although this has been rightly indicated as a hazardous venture due to the low sequence identity (often less than 20% [20]) and the 120 amino acid NBD-TMD linker region which is unique to the ABCG family of transporters and so cannot be modelled reliably from other ABC transporter structures (Figure 1). Models based upon the bacterial NBD MalK (i.e. to model the ABCG2 NBD), bacterial half-transporters Sav1866 and MsbA and the full length mouse ABCB1 have been described and their use to date has been limited to interpreting low resolution electron microscopy (EM) data [33,34]. Improved structural data of ABCG2 in the inward facing, presumably nucleotide-free state have been obtained recently [35], but this is far short of secondary structural resolution; perhaps the incredible advances that have made in data collection and analysis in cryo-EM in recent years (see [36] for a review) will enable us to reach near atomic resolution for ABCG2 in the not Too distant future.

Based on knowledge of other ABC transporters it was probable that ABCG2 would require at least dimerization to form a functional unit. However, evidence for higher order oligomers has come thick and fast. The demonstration of tetramer formation has included native gel electrophoresis and EM [37,38] and other EM studies identified a stable homo-octameric association [33]. More recently, the oligomeric state has been studied in intact membranes in live and fixed cells; both fluorescence correlation spectroscopy and stepwise photobleaching enabled the observation of a predominantly tetrameric organization of ABCG2 in the presence and absence of transport substrates [39]. Understanding the structural basis of oligomerization remains problematic; the entire TM5–TM6 region appears to be involved with some evidence that this helical pair is sufficient for oligomerization to occur [40]. Within this region the single glycosylation site (N596; [41]) and an intramolecular disulfide bond between C592 and C608 [42] are implicated in protein trafficking and stability. A further cysteine residue in the TM5–TM6 extracellular loop (C603) is involved in inter-molecular disulfide bond formation although mutation of this residue does not impede oligomerization nor transport activity [43,44].

When will this structural knowledge enable us to inhibit any unwanted actions of ABCG2? Tellingly, more than a decade on from the initial discovery of ABCG2-specific inhibitors, the mechanism of fumitremorgin C and Ko143 remains obscure [45]. It remains to be seen whether a better understanding of the structural basis for drug interaction, or a better understanding of oligomerization is required to provide a route towards therapeutic inhibition of ABCG2.

**ABCG2 in cancer: did we cry wolf?**

ABCG2 was originally cloned from breast tumour cell lines and placental tissue in 1998 [46–48] and its isolation from a multidrug resistant breast cancer (Mcf7-derived) cell line quickly led to its assignation as the ‘breast cancer resistance protein’. But how justifiable has that moniker proven to be? Indeed, how much of a prognostic indicator is ABCG2 expression in cancer? A trawl of the literature reveals relatively few cancer types where ABCG2 expression (either protein or mRNA) is an independent prognostic indicator of poor clinical outcome. For haematological malignancies there is considerable evidence that ABCG2 is associated with poor outcome in acute myeloid leukaemia [49,50], even after bone marrow transplantation [51], and diffuse large B-cell lymphoma [32]. In some of these studies, co-expression with other MDR pumps (notably ABCB1) was associated with even higher hazard ratios [53,54]. For acute lymphoblastic leukaemia (ALL) the evidence is rather less convincing [55], and in paediatric ALL multiple studies report no association between ABCG2 expression and clinical outcome [56,57]. In solid tumours the picture is very mixed. For many tumour types there are frequently only 1 or 2 studies available precluding any conclusions from being drawn. Even for breast cancer the number of studies remains low with conflicting data presented [58,59]. For lung and oesophageal cancer, which have dismal 5-year survival rates (less than 20%), there is a consensus developing that ABCG2 is a prognostic indicator. In both small cell and non-small cell lung cancer (NSCLC) multiple studies now identify ABCG2 expression as being correlated with lower overall survival, shorter progression-free survival and the response to therapy [52,60–64]. Intriguingly, this applies when the therapy is platinum based, although ABCG2 is not identified as a transporter of Pt-containing drugs.

The identification of ABCG2 as a cancer stem cell marker [65] has led to many papers attempting to identify cancer stem cells co-expressing the marker CD133 and ABCG2, although in only a limited number of cases is co-expression of CD133 and ABCG2 of prognostic significance [61]. Attention is also turning in clinical studies to whether particular SNPs of ABCG2 are predictive of response to treatment, or chemotherapy induced toxicity. Again, haematological malignancies lead the way in these studies although recent data on NSCLC and ovarian cancer indicate that a more fine-grained analysis of ABCG2 haplotypes will uncover clinically relevant findings [66].
Perspective
So what now for ABCG2 research? In our own field (structure and function) we would hope that the bounty of functional data soon has more robust structural models within which these data can be interpreted. That will help us to develop a more complete understanding of how drugs are bound and transported by this MDR pump. It will also help us to interpret the action of small molecule inhibitors of ABCG2, which may emerge to be important in clinical practice. In this regard, we need more studies to examine ABCG2 expression in solid tumours to consolidate the data already in the literature and provide a more definitive picture of this pump’s role in cancer biology.

Funding
This work was supported by the Biotechnology and Biological Sciences Research Council Doctoral Training Partnership studentships [grant number BB/J014508/1 (to A.J.H. and M.H.C.)]; and the University of Nottingham Developing Solutions Scholarship (to S.S.).

References
1. Wong, K., Ma, J., Rothnie, A., Biggin, P.C. and Kerr, I.D. (2014) Towards understanding promiscuity in multidrug efflux pumps. Trends Biochem. Sci. 39, 8–16 CrossRef PubMed
2. Mao, Q. and Unadkat, J.D. (2015) Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport – an update: AAPS J. 17, 65–82 CrossRef PubMed
3. Darby, R.A., Callaghan, R. and McMahon, R.M. (2011) P-glycoprotein inhibition: past, the present and the future. Curr. Drug Metab. 12, 722–731 CrossRef PubMed
4. Jonker, J.W., Buijelaar, M., Wagenaar, E., Van Der Valk, M.A., Scheffer, G.L., Schepers, R.J., Plosch, T., Kupers, F., Ellenrik, R.P., Rosing, H. et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U.S.A. 99, 15649-15654 CrossRef PubMed
5. Haider, A.J., Cox, M.H., Jones, N., Goode, A.J., Bridge, K.S., Wong, K., Briggs, D. and Ken, I.D. (2015) Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABKG sequences. Biosci. Rep. 35, e00241 CrossRef PubMed
6. Aronica, E., Goto, J.A., Redeker, S., van Vliet, E.A., Ramkema, M., Scheffer, G.L., Schepers, R.J., van der Valk, P., Leenstra, S., Baayen, J.C. et al. (2005) Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46, 849–857 CrossRef PubMed
7. Zhang, W., Mijailovic-Petrovic, J., Andrade, M.F., Zhang, H., Hall, B. and Stanimirovic, D.B. (2003) Expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 17, 2085-2087 PubMed
8. Agarwal, S., Sane, R., Olfest, J.R. and Elmqvist, W.F. (2011) The role of breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J. Pharmacol. Exp. Ther. 336, 223-233 CrossRef PubMed
9. Bauer, M., Karch, R., Zeitlinger, M., Stanek, J., Philippe, C., Wadask, W., Mitterhauser, M., Jager, W., Haslacher, H., Muller, M. and Langer, O. (2013) Interaction of 11C-taniquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J. Nucl. Med. 54, 1181-1187 CrossRef PubMed
10. Gutmann, H., Hutz, P., Zimmermann, C., Beglinger, C. and Drewes, J. (2005) Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem. Pharmacol. 70, 695-699 CrossRef PubMed
11. Krüitzer, C.M., Beijnen, J.H., Rosing, H., ten Bokkel Hunnik, W.V., Schot, M., Dwess, R.C., Paul, C.M. and Schellens, J.H. (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20, 2943-2950 CrossRef PubMed
12. Haliepaard, M., Scheffer, G., Finne, T., van Gastelen, A.N., Pirijnberg, A.E., Schinkel, A.H., van De Vijver, M.J., Schepers, R.J. and Schellens, J.H. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458-3464 PubMed
13. Woodward, O.M., Kotting, A., Coresh, J., Boerwinkle, E., Guggino, W.B. and Kotting, M. (2009) Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. U.S.A. 106, 10338-10342 CrossRef PubMed
14. Mao, Q. (2008) BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm. Res. 25, 1244-1255 CrossRef PubMed
15. Jonker, J.W., Merino, G., Musters, S., van Herwaarden, A.E., Bulscher, E., Wagenaar, E., Mesman, E., Dale, I.C. and Schinkel, A.H. (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11, 127-129 CrossRef PubMed
16. van Herwaarden, A.E., Wagenaar, E., Merino, G., Jonker, J.W., Rosing, H., Beijnen, J.H. and Schinkel, A.H. (2007) Mutidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol. Cell. Biol. 27, 1247-1253 CrossRef PubMed
17. Basseville, A., Hall, M.D., Chau, C.H., Robey, R.W., Gottesman, M., Figg, W.D. and Bates, S.E. (2016) The ABCG2 multidrug transporter. In ABC Transporters – 40 Years On (George, A.M. ed.), pp. 195-226, Springer, Heidelberg CrossRef
18. Yoshikawa, M., Ikigami, Y., Hayasaka, S., Ishii, K., Ito, A., Sano, K., Suzuki, T., Togawa, T., Yoshida, H., Soda, H. et al. (2004) Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int. J. Cancer 110, 921-927 CrossRef PubMed
19. Gozzi, G.J., Bouaziz, Z., Winter, E., Dall’Oneto, N., Honorat, M., Mutter, K., Parmar, C., Bollack, A., Guillou, J. et al. (2015) Phenolic indoles 1,2-b-jbindoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity. Drug Dev. Ther. 9, 3481-3495
20. Xu, Y., Eidgo, E., Li-Blatter, X., Muller, R., Merino, G., Berneche, S. and Seelig, A. (2015) Alloence sensing and binding by the breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1). Biochemistry 54, 6195-6206 CrossRef PubMed
21. Eidgo, E., Muller, R., Li-Blatter, X., Merino, G. and Seelig, A. (2015) Predicting activators and inhibitors of the breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) based on mechanistic considerations. Mol. Pharm. 12, 4026-4037 CrossRef PubMed
22. Clark, R., Kerr, I.D. and Callaghan, R. (2006) Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br. J. Pharmacol. 149, 505-515 CrossRef PubMed
23. McDevitt, C.A., Crowley, E., Hobbs, G., Starr, K.J., Kerr, I.D. and Callaghan, R. (2006) ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2? FEBS J. 275, 4354-4362 CrossRef PubMed
24. Ejendal, K.F., Diop, N.K., Schweiger, L.C. and Hrycyna, C.A. (2006) The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci. 15, 1597–1607 CrossRef PubMed
25. Robey, R.W., Honjo, Y., Morisaki, K., Nadjem, T.A., Runge, S., Risbood, M., Poruchynsky, M.S. and Bates, S. E. (2003) Mutations at amino-acid 482 of human ABCG2 affect substrate and antagonist specificity. Br. J. Cancer 89, 1971–1978 CrossRef PubMed
26. Ni, Z., Bikadi, Z., Cai, X., Rosenberg, M.F. and Mao, Q. (2010) Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport. Am. J. Physiol., Cell Physiol. 299, C1100-C1109 CrossRef PubMed
27. Ni, Z., Bikadi, Z., Shuster, D.L., Zhao, C., Rosenberg, M.F. and Mao, Q. (2011) Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity. Biochemistry 50, 8057-8066 CrossRef PubMed

© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY-NC).
4.0 (CC BY-NC-ND).
63 Tsunoda, S., Okumura, T., Ito, T., Kondo, K., Ortiz, C., Tanaka, E., Watanabe, G., Itami, A., Sakai, Y. and Shimada, Y. (2006) ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology 71, 251–258 CrossRef PubMed

64 Yoh, K., Ishii, G., Yokose, T., Minegishi, Y., Tsuta, K., Goto, K., Nishiwaki, Y., Kodama, T., Suga, M. and Ochiai, A. (2004) Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin. Cancer Res. 10, 1691–1697 CrossRef PubMed

65 Hirschmann-Jax, C., Foster, A.E., Wulf, G.G., Nuchtern, J.G., Jax, T.W., Gobel, U., Goodell, M.A. and Brenner, M.K. (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U.S.A. 101, 14228–14233 CrossRef PubMed

66 Tian, C., Ambrosone, C.B., Darcy, K.M., Krivak, T.C., Armstrong, D.K., Bookman, M.A., Davis, W., Zhao, H., Moysich, K., Gallion, H. and DeLoia, J.A. (2012) Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol. Oncol. 124, 575–581 CrossRef PubMed

Received 15 January 2016
doi:10.1042/BST20160014